PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Depression
Interventions
DRUG

Racemic ketamine

Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.

DRUG

Spravato (Esketamine)

Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.

Trial Locations (6)

30322

RECRUITING

Emory University, Atlanta

48104

RECRUITING

University of Michigan, Ann Arbor

73160

RECRUITING

LifeStance Health, Moore

77401

RECRUITING

Houston Center for Advanced Psychiatric Treatment, Bellaire

06461

RECRUITING

Mood Institute, Milford

06512

RECRUITING

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Yale University

OTHER